benralizumab

benralizumab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Severe Eosinophilic Asthma、Asthma、Eosinophilic Granulomatosis With Polyangiitis (EGPA)、Hypereosinophilic Syndrome (HES)。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 benralizumab 研究

• 3TR Asthma Biologics Cohort (ABC) Study

  不适用招募中丹麦荷兰NCT06126692

• This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab

  不适用招募中中国NCT06862206

• Taiwan Severe Asthma Biologic Registry

  不适用招募中中国台湾NCT06456450

• A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases

  III 期招募中美国Brazil加拿大法国NCT06512883

• Predictive Signature of Benralizumab Response

  IV 期招募中法国NCT04565483

• Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents

  II 期招募中美国NCT06477653

• A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy

  不适用招募中意大利NCT07214753

• Benralizumab Effectiveness in EGPA

  不适用招募中意大利NCT07815886

• Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis

  不适用招募中中国NCT07530770

• BIOlogics in Severe Nasal POlyposis SurvEy.: a French Registry

  不适用招募中法国NCT06501807

• Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping

  IV 期招募中美国NCT06385236

• Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment

  III 期招募中美国Argentina奥地利比利时NCT07444567

• T2AIR: Real-World Efficacy and Safety of Biologics Targeting Type 2 Inflammation in Asthma and COPD

  不适用招募中中国NCT07823842

• A Non-interventional, Prospective Study With Benralizumab

  不适用招募中德国NCT06422078

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。